{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:31:06Z","timestamp":1767987066195,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Secondary hyperparathyroidism (SHPT) of renal origin is a progressive complication in chronic kidney disease (CKD) and is associated with serious osseous and non-osseous complications, CKD progression, and economic burden for healthcare systems worldwide. We aimed at assessing characteristics, healthcare resource utilization, and costs of incident SHPT patients in CKD stage 3 (CKD3) and 4 (CKD4), using administrative claims data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>German claims data were used to identify CKD3 and CKD4 patients, who were stratified by the occurrence of incident SHPT. Patients with SHPT were matched 1:1 to non-SHPT patients with the same CKD stage using propensity scores. Matched groups were compared during a 2-year follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1156 CKD3 and 517 CKD4 incident SHPT patients and their respective matches were identified. Mean number of all-cause hospitalizations were significantly higher among SHPT patients (2.7 vs. 2.0 in CKD3, 2.8 vs. 1.5 in CKD4) during follow-up. Similarly, the mean number of outpatient encounters was significantly higher among the SHPT cohorts (95.0 vs. 64.3 in CKD3, 101.4 vs. 49.8 in CKD4). SHPT patients progressed to CKD5 more often (6.1% vs. 1.2% from CKD3, 26.7% vs. 2.9% from CKD4, both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) resulting in a higher proportion of dialysis (6.1% vs. 1.3% in CKD3, 22.1% vs. 3.7% in CKD4, both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Consequently, average all-cause healthcare costs significantly increased per patient (\u20ac19,477 vs. \u20ac15,115 in CKD3, \u20ac25,921 vs. \u20ac12,265 in CKD4).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with CKD3&amp;4 and incident SHPT of renal origin presented with significantly higher healthcare resource utilization and costs, as well as increased disease progression compared to non-SHPT patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-022-03425-9","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:10:58Z","timestamp":1670515858000},"page":"1291-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Economic burden of secondary hyperparathyroidism in Germany: a matched comparison"],"prefix":"10.1007","volume":"55","author":[{"given":"Helmut","family":"Reichel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank-Peter","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Barck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astride","family":"Grava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Maren","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-3137","authenticated-orcid":false,"given":"Dominic","family":"Meise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"7","key":"3425_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, Hobbs FD (2016) Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS ONE 11(7):e0158765. https:\/\/doi.org\/10.1371\/journal.pone.0158765","journal-title":"PLoS ONE"},{"issue":"10225","key":"3425_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"G. B. D. Chronic Kidney Disease Col","year":"2020","unstructured":"G. B. D. Chronic Kidney Disease Collaboration, (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"issue":"3","key":"3425_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z (2018) Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94(3):567\u2013581. https:\/\/doi.org\/10.1016\/j.kint.2018.04.011","journal-title":"Kidney Int"},{"issue":"4","key":"3425_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913\u2013921. https:\/\/doi.org\/10.2215\/CJN.06040710","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"3425_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10157-016-1369-2","volume":"21","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kakuta T, Fukagawa M (2017) Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol 21(Suppl 1):37\u201345. https:\/\/doi.org\/10.1007\/s10157-016-1369-2","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"3425_CR6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40620-021-01082-2","volume":"34","author":"M Ketteler","year":"2021","unstructured":"Ketteler M, Ambuhl P (2021) Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. J Nephrol 34(5):1405\u20131418. https:\/\/doi.org\/10.1007\/s40620-021-01082-2","journal-title":"J Nephrol"},{"issue":"1","key":"3425_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4158\/EP.14.1.18","volume":"14","author":"DL Andress","year":"2008","unstructured":"Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM (2008) Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract 14(1):18\u201327. https:\/\/doi.org\/10.4158\/EP.14.1.18","journal-title":"Endocr Pract"},{"issue":"1","key":"3425_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31\u201338. https:\/\/doi.org\/10.1038\/sj.ki.5002009","journal-title":"Kidney Int"},{"key":"3425_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab184","author":"M Bozic","year":"2021","unstructured":"Bozic M, Diaz-Tocados J, Bermudez-Lopez M, Forne C, Martinez C, Fernandez E, Valdivielso J (2021) Independent effects of secondary hyperparathyroidism and hyperphosphatemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab184","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3425_CR10","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","volume":"30","author":"S Geng","year":"2019","unstructured":"Geng S, Kuang Z, Peissig PL, Page D, Maursetter L, Hansen KE (2019) Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int 30(10):2019\u20132025. https:\/\/doi.org\/10.1007\/s00198-019-05033-3","journal-title":"Osteoporos Int"},{"key":"3425_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab006","author":"Y Xu","year":"2021","unstructured":"Xu Y, Evans M, Soro M, Barany P, Carrero JJ (2021) Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfab006","journal-title":"Clin Kidney J"},{"key":"3425_CR12","unstructured":"Lee A, Belozeroff V, Song X, Diakun D, Goodman W (2013) Costs of Treatment and Clinical Events for Secondary Hyperparathyroidism. Am J Pharm Benefits 5(2):e24\u2013e35"},{"issue":"1","key":"3425_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J (2016) Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf 25(1):106\u2013109. https:\/\/doi.org\/10.1002\/pds.3895","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3425_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"issue":"3","key":"3425_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"P Austin","year":"2011","unstructured":"Austin P (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"issue":"5","key":"3425_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.18553\/jmcp.2007.13.5.397","volume":"13","author":"MS Joy","year":"2007","unstructured":"Joy MS, Karagiannis PC, Peyerl FW (2007) Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13(5):397\u2013411. https:\/\/doi.org\/10.18553\/jmcp.2007.13.5.397","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"3425_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO","year":"2017","unstructured":"KDIGO (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"3425_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ndt\/gfz260","volume":"35","author":"H Reichel","year":"2020","unstructured":"Reichel H, Zee J, Tu C, Young E, Pisoni RL, Stengel B, Duttlinger J, Lonnemann G, Robinson BM, Pecoits-Filho R, Fliser D (2020) Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study. Nephrol Dial Transplant 35(5):803\u2013810. https:\/\/doi.org\/10.1093\/ndt\/gfz260","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3425_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000073945","volume":"23","author":"SM Moe","year":"2003","unstructured":"Moe SM, Drueke TB (2003) Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23(6):369\u2013379. https:\/\/doi.org\/10.1159\/000073945","journal-title":"Am J Nephrol"},{"issue":"11","key":"3425_CR20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/ki.2008.64","volume":"73","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73(11):1296\u20131302. https:\/\/doi.org\/10.1038\/ki.2008.64","journal-title":"Kidney Int"},{"issue":"6","key":"3425_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1053\/ajkd.2001.29254","volume":"38","author":"M Avram","year":"2001","unstructured":"Avram M, Mittman N, Myint M, Fein P (2001) Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38(6):1351\u20131357. https:\/\/doi.org\/10.1053\/ajkd.2001.29254","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3425_CR22","doi-asserted-by":"publisher","first-page":"E274","DOI":"10.1503\/cmaj.181372","volume":"191","author":"P Liu","year":"2019","unstructured":"Liu P, Quinn RR, Karim ME, Bello A, Tam-Tham H, Weaver R, Ronksley PE, Quan H, Strippoli GFM, Manns B, Hemmelgarn BR, Tonelli M, Ravani P (2019) Nephrology consultation and mortality in people with stage 4 chronic kidney disease: a population-based study. CMAJ 191(10):E274\u2013E282. https:\/\/doi.org\/10.1503\/cmaj.181372","journal-title":"CMAJ"},{"issue":"3","key":"3425_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2215\/cjn.03540708","volume":"4","author":"T Hasegawa","year":"2009","unstructured":"Hasegawa T, Bragg-Gresham JL, Yamazaki S, Fukuhara S, Akizawa T, Kleophas W, Greenwood R, Pisoni RL (2009) Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol 4(3):595\u2013602. https:\/\/doi.org\/10.2215\/cjn.03540708","journal-title":"Clin J Am Soc Nephrol"},{"key":"3425_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2369-13-140","volume":"13","author":"S Chiroli","year":"2012","unstructured":"Chiroli S, Mattin C, Belozeroff V, Perrault L, Mitchell D, Gioni I (2012) Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study. BMC Nephrol 13:140. https:\/\/doi.org\/10.1186\/1471-2369-13-140","journal-title":"BMC Nephrol"},{"issue":"11","key":"3425_CR25","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1185\/03007990802437943","volume":"24","author":"GT Schumock","year":"2008","unstructured":"Schumock GT, Andress D, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K (2008) Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin 24(11):3037\u20133048. https:\/\/doi.org\/10.1185\/03007990802437943","journal-title":"Curr Med Res Opin"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03425-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:11:20Z","timestamp":1681564280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03425-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["3425"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03425-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}